RC148 is a humanized IgG1 silenced bispecific antibody targeting VEGF and PD-1. RC148 allows dimeric VEGF crosslinking and gradually enhances PD-1 binding activity, potentially reduces systemic toxicity of the anti-VEGF approach, and enhances antitumor potency via VEGF-triggered enrichment in tumor areas. RC148 blocks the binding of VEGF to VEGFR and PD-1 to PD-L1, prevents the growth and migration of human umbilical vein endothelial cells, and enables efficient T cell activation. RC148 can be used for the study of breast cancer and lung cancer[1].
